Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding molecular biology. Fulcrum Therapeutics’ 10-K is packed with gene-expression charts, DUX4 risk factors, and cash-runway tables that easily exceed 200 pages. Finding the latest losmapimod trial update or the cost of developing pociredir isn’t straightforward—and missing those details can skew valuation models.
Stock Titan solves that problem. Our AI engine breaks down every Fulcrum Therapeutics SEC filing—whether it’s a Fulcrum Therapeutics annual report 10-K simplified or a Fulcrum Therapeutics quarterly earnings report 10-Q filing—into concise highlights, then links directly to the full text on EDGAR. Need real-time alerts? We push Fulcrum Therapeutics Form 4 insider transactions real-time to your dashboard, so you know when executives buy or sell ahead of pivotal readouts. You can also skim an 8-K material events explained summary minutes after it posts.
Here’s what you can do on this page:
- Track Fulcrum Therapeutics insider trading Form 4 transactions and spot buying patterns before Phase 3 data drops.
- Compare R&D spend across quarters with an AI-annotated earnings report filing analysis.
- Review the proxy statement executive compensation section to see how milestones drive management bonuses.
- Use "understanding Fulcrum Therapeutics SEC documents with AI" guides to decode complex gene-regulation jargon.
Whether you’re modeling burn rate, watching for orphan-drug status updates, or verifying executive stock transactions Form 4, Stock Titan surfaces the insights buried deep inside each form—so you can act before the market does.
Fulcrum Therapeutics director reports sale of common stock under trading plan. A reporting person serving as a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction at a weighted average price of $11.033 per share. After this sale, the individual beneficially owns 484,864 shares of Fulcrum common stock in direct form. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 1, 2025, which is intended to allow systematic selling according to preset instructions.
Fulcrum Therapeutics (FULC) filed its Q3 2025 10‑Q, reporting continued operating focus on sickle cell candidate pociredir alongside tighter expenses. The quarter showed a net loss of $19.6 million on operating expenses of $21.9 million (R&D $14.3 million; G&A $7.6 million). Cash, cash equivalents, and marketable securities totaled $200.6 million as of September 30, 2025, and management states this should fund operations for at least 12 months from issuance. The accumulated deficit was $573.9 million.
Clinical update: In the 12 mg Phase 1b cohort (n=16), pociredir increased mean absolute fetal hemoglobin (HbF) by 8.6% at 12 weeks (7.6% to 16.2%); 7 of 16 exceeded 20% HbF. Hemolysis markers improved and mean hemoglobin rose by 0.9 g/dL. Safety was generally well-tolerated with no drug‑related serious adverse events or discontinuations. Enrollment in the 20 mg cohort (n=12) is complete, with data expected by the end of 2025.
There was no collaboration revenue in Q3 2025 (vs. $80.0 million in the first nine months of 2024 from a now-terminated Sanofi agreement). Shares outstanding were 54,118,438 as of October 22, 2025.
Fulcrum Therapeutics (FULC) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025. A detailed press release was furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under the Exchange Act. Fulcrum’s common stock trades on the Nasdaq Global Market under the symbol FULC.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.
The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
